Independent Peptide Research Catalog

A small-molecule NNMT inhibitor that reduces adipocyte size and body weight in obese mice without changing food intake. Marketed as a peptide. It is not one. No human trials exist.

Recombinant fusion protein combining the extracellular domain of activin receptor IIB with human IgG1 Fc. Phase 2 trials in Duchenne muscular dystrophy halted due to bleeding events. Development discontinued.

Vascular-targeting chimeric peptide ablating adipose blood supply; Phase 1 discontinued at MD Anderson 2012-2014 due to renal toxicity concerns.

Copper-binding tripeptide (Ala-His-Lys) developed as a cosmetic ingredient for hair-follicle and skin applications. Less-studied sister compound to GHK-Cu. Cosmetic-grade evidence base only.

Purine nucleoside (Acadesine) that mimics AMP after intracellular phosphorylation, activating AMPK and triggering exercise-like metabolic effects. Endurance mimetic. WADA-banned at all times since 2009. Investigational in cardiovascular and oncology contexts. No FDA approval.

Once-weekly GLP-1 receptor agonist FDA-approved 2014 (Tanzeum, GSK). Recombinant fusion of two GLP-1 copies with human serum albumin. Withdrawn from worldwide market in 2017-2018 by GSK for commercial reasons despite cardiovascular benefit demonstrated in HARMONY Outcomes.

Cardiolipin-binding tetrapeptide that stabilizes the inner mitochondrial membrane. FDA-approved as Forzinity for Barth syndrome in September 2025.

Small-molecule mitochondrial protonophore that uncouples oxidative phosphorylation. Animal obesity and metabolic disease data only. Not a peptide. No human trial.

Synthetic Glu-Asp dipeptide developed by the Khavinson group as a bladder cytogen. Evidence is dominated by Russian-institution publications. No FDA approval, no Western RCT, no peer-reviewed pharmacokinetic data.

Khavinson tripeptide bioregulator (Lys-Glu-Asp) targeting vascular endothelium. Developed at the St. Petersburg Institute of Bioregulation and Gerontology. Russian preclinical research only. No Western clinical trials. Available as supplement in Russia.

Khavinson dipeptide bioregulator (Lys-Glu) targeting thymus and immune system. Developed at the St. Petersburg Institute of Bioregulation and Gerontology. Animal studies report immune restoration in aged animals and lifespan extension. No Western clinical trials.

Modified C-terminal hGH fragment investigated for fat loss; failed primary endpoint in Phase 2b trial.